Abstract:OBJECTIVE:To evaluate the potential role of tegaserod in the management of functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) in patients with chronic constipation and to determine the possible efficacy of tegaserod on solid-phase gastric emptying and gastric hypersensitivity.METHOD:This was an exploratory open-label trial of tegaserod therapy for dyspepsia and reflux symptoms in patients with chronic constipation. The study cohort consisted of 90 patients randomized to three treatment groups for a study period of 4 weeks (tegaserod 6 mg, twice daily; esomeprazole 40 mg, once daily; tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily). Twenty healthy volunteers provided control values. Clinical symptoms were evaluated by one of the investigators using a Gastrointestinal Symptom Rating Scale (GSRS). Solid-phase gastric emptying and colonic transit were measured by the radiopaque barium marker method, and the water load test (WLT) was used to evaluate gastric sensation and the function of proximal stomach. The proportions of patients with complete relief of epigastric pain /discomfort, epigastric fullness, early satiety and heartburn in the tegaserod group and the tegaserod plus esomeprazole group were compared with the esomeprazole group, respectively.RESULTS:The mean global gastrointestinal (GI) scores of all three treatment groups reported using the GSRS showed the same trend, with decreasing scores over the 4-week study period indicating a reported decreasing severity of symptoms that was significantly different from baseline values. Patients in the tegaserod plus esomeprazole group reported the lowest global GI scores after 4 weeks, as expected. Solid-phase gastric emptying (GER) and colonic transit (CTT) increased significantly in the tegaserod 6 mg twice daily group compared with baseline. These parameters did not change in the esomeprazole group at week 4 compared with baseline. In terms of gastric sensation, in the tegaserod group, the proportions of patients with hypersensitivity of the first perception threshold did not change at week 2 or week 4 compared with baseline; however, in this group and in the tegaserod plus esomeprazole group, the proportions of patients with hypersensitivity of discomfort threshold decreased significantly at week 4 compared with baseline. In the esomeprazole group, there were no changes in the proportions of patients with hypersensitivity of the first perception threshold and discomfort threshold at week 2 or 4 compared with baseline. No severe adverse events were recorded, and the medications were in general well-tolerated.CONCLUSION:Tegaserod is effective and safe at improving dyspepsia and reflux symptoms in patients with chronic constipation, and tegaserod plus esomeprazole is superior to esomeprazole alone in the resolution of epigastric pain/discomfort and heartburn.

The Effect of Itopride on Reflux Symptom and Esophageal Motility in Cases of Non-erosive Reflux Disease with Dysmotility

The efficacy and safety of itopride as an add-on therapy to a proton pump inhibitor in the treatment of gastroesophageal reflux disease

Itopride in Treatment of 104 Patients with Functional Dyspepsia: a Randomized, Double-Blind Controlled Clinical Trial

The efficacy and safety of itopride in feeding intolerance of critically ill patients receiving enteral nutrition: a randomized, double-blind study

The effect of acupuncture on reflux symptom and esophageal motility in cases of non-erosive reflus disease with dysmotility

Effects of Esomeprazole Combined with Trimebutine in Treatment for Non-Erosive Reflux Disease

Clinical observation and esophageal dynamical analysis of esomeprazole combined with itopride in the treatment of gastroesophageal relfux disease

Efficacy of Itopride in Functional Dyspepsia Patients Overlapping Constipation-Predominant Irritable Bowel Syndrome

Itopride and Citalopram in Treatment of Functional Dyspepsia

Analysis of the Effect of Omeprazole and Tegaserod on Non-Erosive Reflux Disease

Itopride in the Treatment of Functional Dyspepsia in Chinese Patients

The Effect of Esomeprazole on Reflux Esophagitis

Multicentric short term and safety study of ineffective esophageal motility patients treated with RefluxStop device

Tegaserod for Dyspepsia and Reflux Symptoms in Patients with Chronic Constipation: an Exploratory Open-Label Study

Clinical Observation on Jiangni Hewei Decoction in Treatment of Nonerosive Reflux Disease

Effects of Itopride Prior to Capsule Endoscopy

Healing of Severe Reflux Esophagitis with Ppi Does Not Improve Esophageal Dysmotility

Role of Itopride in the Improvement of Bowel Preparation Before Colon Endoscopy Examination in Constipated Patients

Randomized Controlled Trial of Transoral Incisionless Fundoplication Vs. Proton Pump Inhibitors for Treatment of Gastroesophageal Reflux Disease

Effects of Combined Treatment with Itopride,Lansoprazole and Flupentixol Melitracen and Psychological Intervention on Functional Dyspepsia

Efficacy of mosapride therapy on gastroesophageal reflux disease: A randomized, double-blind, placebo-controlled cross-over study